Axogen (AXGN) FY2025 10-K Risk Factors: 9 New, 7 Dropped

What the changes say

Axogen secured FDA BLA approval for its Avance nerve graft product in December 2025, shifting risks to post-approval compliance and clinical study requirements.
Accumulated deficit grew to $307.0 million with 2025 net losses of $15.7 million.
New CMS payment categories created new reimbursement opportunities.

What changed since the prior 10-K

New

NewRisks Related to Our Business and Strategy
If our estimates of the TAM for peripheral nerve repair and reconstruction are inaccurate, our growth prospects and financial performance could be materially adversely affected
Inaccurate estimates of the total addressable market for peripheral nerve repair could limit revenue growth and execution of long-term strategy.
NewRisks Related to Our Business and Strategy
Effective January 1, 2026, CMS created a new Ambulatory Payment Category 5433 for level 3 nerve repair. CPT 64912 was moved into this new code group, which further improves payment adequacy for advanced nerve repair
CMS created a new Ambulatory Payment Category 5433 for level 3 nerve repair, improving payment adequacy for Avance Nerve Graft and other products.
NewRisks Related to Our Business and Strategy
increased 96% in hospital outpatient centers and 126% in ambulatory surgery centers. While Medicare patients represent a relatively small percentage of trauma cases, CMS’ direction often influences commercial payor policies and payments
Commercial payors covering significant U.S. lives maintain legacy non-coverage policies designating Avance Nerve Graft and Axoguard as investigational or experimental.
NewRisks Related to Our Business and Strategy
We are currently operating in a period of economic uncertainty and capital markets volatility driven in part by growing geopolitical tensions and evolving global security risks, any of which could materially and adversely affect our business, financial condition and results of operations
Economic uncertainty and geopolitical tensions, including U.S.-China trade friction and Middle East instability, could disrupt supply chains and increase costs.
NewRisks Related to the Regulatory Environment in which We Operate
In addition, all promotional materials for products approved under the accelerated approval pathway are subject to prior review by the FDA. If the FDA were to object to our promotional pieces, we may be required to revise our materials, or be subject to untitled or warning letters
Promotional materials for products approved under the accelerated approval pathway are subject to prior FDA review and potential warning letters.
NewRisks Related to the Regulatory Environment in which We Operate
If the FDA were to withdraw or suspend our BLA approval, narrow the approved indication, or otherwise limit the use of our Avance Products, our revenues would be significantly impacted and thus would have a material adverse effect on us
Because Avance products generate approximately 60% of total revenues, any FDA withdrawal of the BLA or narrowed indication would significantly harm operations.
NewRisks Related to the Regulatory Environment in which We Operate
Failure to obtain regulatory or other approvals from certain states in which we operate after BLA approval for Avance could delay, hinder, or prevent commercialization of our products
State tissue banking regulations in Florida, New York, California, and Maryland require separate approvals and licensing following the Avance BLA.
NewRisks Related to Our Intellectual Property
The patent protection for our products may expire before we are able to maximize their commercial value, which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue
Material U.S. patents covering formulations used in the Axoguard Product Line held by Evergen have expired, increasing competition risks.
NewRisks Related to Our Common Stock
Anti-takeover provisions in Minnesota law may deter acquisition bids for us that you might consider favorable
Anti-takeover provisions under Minnesota law sections 302A.671, 302A.673, and 302A.675 may deter acquisition bids and prevent shareholder premiums.

Dropped

DroppedRisks Related to Our Business and Strategy
Macroeconomic trends, such as the inflationary pressure, and political instability could continue to have a material adverse effect on our ability to operate, results of operations, financial condition, liquidity, and capital investments
DroppedRisks Related to Our Business and Strategy
Failure to successfully manage the transition associated with the recent management changes could have an adverse impact on our business
DroppedRisks Related to Our Business and Strategy
We must maintain high quality processing of our products
DroppedRisks Related to Our Business and Strategy
Our results of operations could be negatively affected by potential fluctuations in foreign currency exchange rates
DroppedRisks Related to Our Business and Strategy
Our business, results of operations, financial condition, and prospects could be adversely affected, directly or indirectly, by the effects of a focus on environmental, social and governance issues
DroppedRisks Related to the Regulatory Environment in which We Operate
false claims for reimbursement, or exclusion from participation in federal health programs. In that event, our reputation could be damaged, and our products’ use in the marketplace could be impaired
Macroeconomic inflation, interest rates, and geopolitical instability impact operations.
DroppedRisks Related to Financing Our Business
extended period of time and are subject to acceleration in specified circumstances, which may result in Oberland Capital taking possession and disposing of any collateral

Reworded

98% rewrittenRisks Related to Our Business and Strategy
Approximately 60% of our total revenues are from sales of Avance Products and any adverse decision from the FDA would negatively impact our operations and financial condition
Updated to reflect that the FDA approved the Avance BLA on December 3, 2025, replacing previous transition plan and enforcement discretion language.
Was: Approximately 60% of our total revenues are from sales of Avance Nerve Graft and any adverse decision from the FDA would negatively impact our operations and financial condition
90% rewrittenRisks Related to the Regulatory Environment in which We Operate
Clinical trials can be long and expensive, and results are ultimately uncertain
Added specific post-marketing study requirements and deadlines for Avance, including a comparative study against nerve autograft due by December 2030.
90% rewrittenRisks Related to Our Business and Strategy
We may be subject to future product liability litigation, which could be expensive, and our insurance coverage may not be adequate
Retained standard product liability risk language regarding potential future claims and insurance adequacy.
86% rewrittenRisks Related to Our Common Stock
We do not anticipate paying any cash dividends in the foreseeable future
Minor style update referencing the Board as Board instead of Board of Directors.
81% rewrittenRisks Related to the Regulatory Environment in which We Operate
BLA approval for Avance could result in different protocols for hospitals’ access to the product, as well as different coverage and reimbursement protocols, both of which may negatively affect surgeons’ access to, revenues derived from, and profitability of, Avance Products
Expanded on how BLA approval for Avance may introduce new hospital and surgical facility supply processes and pharmacy protocols.
Was: BLA approval for Avance Nerve Graft could result in different protocol to hospitals access for the product, as well as different reimbursement protocols, both of which may negatively affect surgeons’ access to, revenues derived from and profitability of Avance Nerve Graft
68% rewrittenRisks Related to Our Business and Strategy
We have a history of net losses and have not consistently experienced positive cash flow from operations, and our ability to achieve consistent positive cash flow will depend on increasing revenue from distribution of our products, which may not be achievable
Updated financial figures for fiscal year 2025, showing net losses of $15.7 million and an accumulated deficit of approximately $307.0 million.
61% rewrittenRisks Related to Our Business and Strategy
Our revenue depends upon prompt and adequate reimbursement from public and private insurers and national health systems
Maintained general text regarding third-party payor reimbursement dependence for hospitals and ambulatory surgery centers.
58% rewrittenRisks Related to Our Business and Strategy
Changes in the tax code could have a material adverse effect on our results of operations, financial condition, liquidity, and capital investments
Added specific reference to the One Big Beautiful Bill Act signed on July 4, 2025, making TCJA provisions permanent.
43% rewrittenRisks Related to the Regulatory Environment in which We Operate
The use, misuse or off-label use of our products may harm our reputation and the reputation of our products, which could result in injuries leading to product liability suits, and could be costly to our business, and/or result in FDA sanctions
38% rewrittenRisks Related to the Regulatory Environment in which We Operate
U.S. governmental regulation could restrict the use of our Avance Products, restrict our procurement of tissue or increase costs
Was: U.S. governmental regulation could restrict the use of our Avance Nerve Graft product, restrict our procurement of tissue or increase costs
35% rewrittenRisks Related to the Regulatory Environment in which We Operate
Our business is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and could result in negative effects on our business
34% rewrittenRisks Related to Our Business and Strategy
We may be unsuccessful in commercializing our products outside the U.S
31% rewrittenRisks Related to the Regulatory Environment in which We Operate
Our operations must comply with FDA and other governmental requirements
30% rewrittenRisks Related to Our Business and Strategy
We are highly dependent on the continued availability of our facilities and could be harmed if we continue to experience operating challenges with our APC Facility or if any of our facilities are unavailable for any prolonged period of time
21% rewrittenRisks Related to Our Intellectual Property
Future protection for our proprietary rights is uncertain and may impact our ability to successfully compete in our industry
21% rewrittenRisks Related to Our Business and Strategy
We are dependent on our relationships with independent agencies to generate a material portion of our revenue
21% rewrittenRisks Related to Our Business and Strategy
Our revenue depends on a limited number of products
20% rewrittenRisks Related to the Regulatory Environment in which We Operate
Failure to obtain regulatory and pricing approvals in foreign jurisdictions after BLA approval for Avance or our other products could delay or prevent commercialization of our products abroad
Was: Failure to obtain regulatory and pricing approvals in foreign jurisdictions after BLA approval for Avance Nerve Graft or our other products could delay or prevent commercialization of our products abroad

All 60 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Business and Strategy

01Approximately 60% of our total revenues are from sales of Avance Products and any adverse decision from the FDA would negatively impact our operations and financial condition98% rewritten
02Our revenue growth depends on our ability to increase distribution and sales to existing customers and develop new customers, domestically and internationally, and there can be no assurance that these efforts will result in significant increases in sales
03We are highly dependent on the continued availability of our facilities and could be harmed if we continue to experience operating challenges with our APC Facility or if any of our facilities are unavailable for any prolonged period of time30% rewritten
04If our estimates of the TAM for peripheral nerve repair and reconstruction are inaccurate, our growth prospects and financial performance could be materially adversely affectedNew
05Our revenue depends on a limited number of products21% rewritten
06Our revenue depends upon prompt and adequate reimbursement from public and private insurers and national health systems61% rewritten
07Effective January 1, 2026, CMS created a new Ambulatory Payment Category 5433 for level 3 nerve repair. CPT 64912 was moved into this new code group, which further improves payment adequacy for advanced nerve repairNew
08increased 96% in hospital outpatient centers and 126% in ambulatory surgery centers. While Medicare patients represent a relatively small percentage of trauma cases, CMS’ direction often influences commercial payor policies and paymentsNew
09Our operating results could be adversely impacted if we are unable to effectively manage and sustain our future growth or scale our operations
10Our success will be dependent on continued acceptance of our products by the medical community
11If we do not manage product inventory in an effective and efficient manner, it could adversely affect profitability
12There may be significant fluctuations in our operating results
13We have a history of net losses and have not consistently experienced positive cash flow from operations, and our ability to achieve consistent positive cash flow will depend on increasing revenue from distribution of our products, which may not be achievable68% rewritten
14Loss of key members of management, who we need to succeed, could adversely affect our business
15Delays, interruptions, or the cessation of production by our third-party suppliers, including products supplied by single suppliers, of important materials may prevent or delay our ability to manufacture or process the final products
16Technological change and competition for newly developed products could reduce demand for our products
17We may not be successful in our efforts to build a pipeline of additional product candidates
18Negative publicity concerning methods of donating human tissue and screening of donated tissue may reduce demand for our products and negatively impact the supply of available donor tissue
19The failure of third parties to perform many necessary services for the commercialization of our products, including services related to recovery/acquisition, sterilization, distribution, and transportation, would impair our ability to meet commercial demand
20We are dependent on our relationships with independent agencies to generate a material portion of our revenue21% rewritten
21We may be unsuccessful in commercializing our products outside the U.S34% rewritten
22We may seek to expand our business in ways that could result in diversion of resources and extra expenses
23We may be subject to future product liability litigation, which could be expensive, and our insurance coverage may not be adequate90% rewritten
24We are currently operating in a period of economic uncertainty and capital markets volatility driven in part by growing geopolitical tensions and evolving global security risks, any of which could materially and adversely affect our business, financial condition and results of operationsNew
25Our failure to protect our technology systems and comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our business, results of operations, financial condition, and prospects
26We are dependent on internal information and telecommunications systems, and any failure of these systems, including system security breaches, data protection breaches or other cybersecurity attacks, may negatively impact our business and results of operations
27Our business and financial performance could be adversely affected, directly or indirectly, by natural or man-made disasters or other similar events
28Changes in the tax code could have a material adverse effect on our results of operations, financial condition, liquidity, and capital investments58% rewritten
29We may have exposure to additional tax liabilities as a result of our foreign operations

Risks Related to the Regulatory Environment in which We Operate

30In addition, all promotional materials for products approved under the accelerated approval pathway are subject to prior review by the FDA. If the FDA were to object to our promotional pieces, we may be required to revise our materials, or be subject to untitled or warning lettersNew
31If the FDA were to withdraw or suspend our BLA approval, narrow the approved indication, or otherwise limit the use of our Avance Products, our revenues would be significantly impacted and thus would have a material adverse effect on usNew
32Our business is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and could result in negative effects on our business35% rewritten
33Failure to obtain regulatory and pricing approvals in foreign jurisdictions after BLA approval for Avance or our other products could delay or prevent commercialization of our products abroad20% rewritten
34The use, misuse or off-label use of our products may harm our reputation and the reputation of our products, which could result in injuries leading to product liability suits, and could be costly to our business, and/or result in FDA sanctions43% rewritten
35U.S. governmental regulation could restrict the use of our Avance Products, restrict our procurement of tissue or increase costs38% rewritten
36Failure to obtain regulatory or other approvals from certain states in which we operate after BLA approval for Avance could delay, hinder, or prevent commercialization of our productsNew
37BLA approval for Avance could result in different protocols for hospitals’ access to the product, as well as different coverage and reimbursement protocols, both of which may negatively affect surgeons’ access to, revenues derived from, and profitability of, Avance Products81% rewritten
38Our Axoguard products are subject to FDA and international regulatory requirements
39Our operations must comply with FDA and other governmental requirements31% rewritten
40Our business is subject to continuing compliance with standards set by various accreditation and registration bodies, which is costly, and loss of accreditation or registration could result in negative effects on our business
41Defective products could lead to recall or other negative business conditions
42Clinical trials can be long and expensive, and results are ultimately uncertain90% rewritten
43We rely on third parties to conduct our clinical trials, and they may not perform as contractually required or expected
44Healthcare law and policy changes may have a material adverse effect on us
45We could be subject to civil or criminal penalties if we are found to have violated laws protecting the confidentiality of health information, which could increase our liabilities and harm our reputation or our business

Risks Related to Our Intellectual Property

46Failure to protect or maintain our IP rights could result in costly and time-consuming litigation and our loss of any potential competitive advantage
47Future protection for our proprietary rights is uncertain and may impact our ability to successfully compete in our industry21% rewritten
48The patent protection for our products may expire before we are able to maximize their commercial value, which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenueNew
49Others may claim an ownership interest in our IP or claim that we infringe on their IP rights, which could expose us to litigation and have a significant adverse effect on our prospects
50Our trademarks are valuable, and our business may be adversely affected if trademarks are not adequately protected
51Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents

Risks Related to Financing Our Business

52We may need to raise additional funds to finance our future capital or operating needs, which could have adverse impacts on our business, results of operations and the interests of our shareholders

Risks Related to Our Common Stock

53An active trading market in our common stock may not be maintained
54The price of our common stock could be volatile due to a number of factors, which could lead to losses by investors and costly securities litigation
55We may fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could cause a decline in our stock price
56We do not anticipate paying any cash dividends in the foreseeable future86% rewritten
57Anti-takeover provisions in Minnesota law may deter acquisition bids for us that you might consider favorableNew
58Our management has broad discretion in the use and placement of our cash and cash equivalents and, despite management’s efforts, cash and cash equivalents may be used in a manner that does not increase the value of shareholders’ investments or placed in otherwise reputable financial institutions that fail

General Risks

59Our business and stock price may be adversely affected if our internal controls are not effective
60We incur costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives

Other Axogen 10-Ks

FY2024 10-K risk factors
58 risks
Axogen relies heavily on Avance Nerve Graft, representing 60% of total revenue and awaiting FDA BLA approval.
Filed Feb 26, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.